Two Phase 3 Trials of Datopotamab Deruxtecan Plus DurvalumabInitiated in Patients Across Two Breast Cancer Subtypes

The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd)…

Read MoreTwo Phase 3 Trials of Datopotamab Deruxtecan Plus DurvalumabInitiated in Patients Across Two Breast Cancer Subtypes

Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its decision today to invest in its Bio drug substance (DS) manufacturing facility “UK3” in the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing…

Read MoreDecision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

Aetna Better Health® of Illinois and Mae Health announce partnership to give members access to local doulas for pregnancy and postpartum health support

Aetna Better Health® of Illinois announced a new partnership with digital health platform Mae Health (“Mae”) to support the maternal health needs of its underserved pregnant and postpartum members in Cook and Kane…

Read MoreAetna Better Health® of Illinois and Mae Health announce partnership to give members access to local doulas for pregnancy and postpartum health support

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel,…

Read MoreGilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program